血栓素A2合成酶抑制剂（OKY - 046）可改善哮喘患者异常的黏液纤毛转运。
Thromboxane A2 synthetase inhibitor (OKY-046) improves abnormal mucociliary transport in asthmatic patients.
作者信息
Kurashima K, Ogawa H, Ohka T, Fujimura M, Matsuda T
机构信息
Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
出版信息
Ann Allergy. 1992 Jan;68(1):53-6.
The effect of a thromboxane A2 synthetase inhibitor (OKY-046, 400 mg po/day) on mucociliary transport was investigated in 19 asthmatic patients. The nasal clearance time, as measured by the saccharin test, was prolonged in asthmatics (60.2 +/- 8.4 SE min) compared with normal controls (15.1 +/- 3.4 SE min). Within 4 weeks after OKY-046 administration, the nasal clearance time had improved (27.4 +/- 4.4 SE min, P less than .01) and the amount of sputum had decreased 30% (P less than .01). These results indicate that thromboxane A2 plays an important role in mucociliary transport in patients with asthma.
在19例哮喘患者中研究了血栓素A2合成酶抑制剂（OKY - 046，口服，每日400毫克）对黏液纤毛运输的影响。通过糖精试验测定，哮喘患者的鼻腔清除时间（60.2±8.4标准误分钟）较正常对照组（15.1±3.4标准误分钟）延长。给予OKY - 046后4周内，鼻腔清除时间有所改善（27.4±4.4标准误分钟，P＜0.01），痰液量减少了30%（P＜0.01）。这些结果表明，血栓素A2在哮喘患者的黏液纤毛运输中起重要作用。
Zotero 插件